Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Total Inventories : $12.35 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Total Inventories?

Tonix Pharmaceuticals Holding's total inventories for the quarter that ended in Mar. 2024 was $12.35 Mil. Tonix Pharmaceuticals Holding's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $13.25 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Tonix Pharmaceuticals Holding's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.19.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Tonix Pharmaceuticals Holding's Days Inventory for the three months ended in Mar. 2024 was 728.30.

Inventory Turnover measures how fast the company turns over its inventory within a year. Tonix Pharmaceuticals Holding's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.13.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Tonix Pharmaceuticals Holding's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 5.34.

Tonix Pharmaceuticals Holding Total Inventories Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Total Inventories Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

14.15

Tonix Pharmaceuticals Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															-	13.70	13.32	14.15	12.35

Tonix Pharmaceuticals Holding Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Tonix Pharmaceuticals Holding (NAS:TNXP) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Tonix Pharmaceuticals Holding's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7.049	+	0.75 * 0	+	0.5 * 12.351	-	27.2
-	0	-	0)	/	73.7242
=	-0.19

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Tonix Pharmaceuticals Holding's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	13.249	/	1.66	*	365 / 4
	=	728.30

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Tonix Pharmaceuticals Holding's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	1.66	/	13.249
	=	0.13

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Tonix Pharmaceuticals Holding's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	13.249	/	2.482
	=	5.34

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Tonix Pharmaceuticals Holding Total Inventories Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Executives

Richard Newcomb Stillwell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman	director, 10 percent owner, officer: Chief Executive Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan	officer: Chief Medical Officer	C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange	director
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris	officer: Chief Administrative Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes	director	74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304